Spero Therapeutics

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Spero Therapeutics reports progress in drug candidates and financial stability

Spero Therapeutics showcased progress in key drug candidates and financial stability.
Efficient management of expenses and strong cash position support future operations.
Challenges include successful Phase III trials and proof of concept for key treatments.
Opportunities lie in market potential for drug candidates and positive financial outlook.

Spero Therapeutics advances clinical programs and strengthens financial position

Spero Therapeutics demonstrated strong clinical and financial performance in Q1 2023, with a robust pipeline and efficient cost management.
While facing timeline challenges and the need for regulatory milestones, the company's strengths in infectious disease treatments and strategic partnerships present growth opportunities.
By addressing challenges, leveraging strengths, and capitalizing on opportunities, Spero is poised for continued success and potential market leadership in the pharmaceutical sector.

Spero Therapeutics reports Q2 progress with strategic leadership changes

Spero Therapeutics reported Q2 revenues of $2.7 million with a net loss of $11.9 million, holding $77.7 million in cash.
Progress in late-stage clinical programs and management changes signal strategic advancements and leadership continuity.
Challenges include managing R&D investments, competitive market dynamics, and clear execution of growth strategies.
Opportunities lie in revenue growth from milestones, pipeline expansion, differentiation strategies, and strategic partnerships.

Spero Therapeutics reports strong Q3 performance amidst strategic shifts

Spero Therapeutics showcased solid revenue generation and cash reserves in Q3 2023, underpinned by strategic partnerships and pipeline advancements.
While facing challenges such as increased expenses and impairment costs, the company's leadership changes and innovative programs position it for long-term success.
Opportunities lie in upcoming clinical data releases, expansion of product pipelines, and substantial revenue potential from key partnerships, signaling a promising outlook for Spero.

Spero Therapeutics excels in antibiotic development with strong financial backing

Spero Therapeutics demonstrated strong performance in advancing key programs and securing financial support, positioning the company for future growth.
While facing challenges in enrollment and funding, the opportunities in addressing critical infections present a promising outlook for Spero Therapeutics.

Spero Therapeutics reports Q2 revenue growth amidst leadership transition

Spero Therapeutics showcased solid revenue but faced rising R&D costs and leadership changes.
The company's financial stability is supported by cash reserves and expected milestone payments.
Opportunities lie in pipeline advancements, upcoming data releases, and strategic investor communication.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Ted Jenkins - Vice President, Investor Relations and Strategic Finance Sath Shukla - Chief Executive Officer Kamal Hamed - Chief Medical Officer Steve Dipalma - Interim Chief Financial Officer and Treasurer Conference Call Participants Louise Chen - Cantor Fitzgerald Boobalan Pachaiyappan - H.C. Wainwright Good afternoon and welcome to the Spero Therapeutics Third Quarter 2023 Financial Results Conference Call.

Spero Therapeutics, Inc. (SPRO) Q3 2023 Earnings Call Transcript

CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Monday, November 13, 2023 at 4:30 p.m. ET to report its third quarter 2023 financial results and provide an update on its business and pipeline.

Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Spero Therapeutics, Inc. (NASDAQ: SPRO) on behalf of long-term stockholders following a class action complaint that was filed against Spero with a Class Period from October 28, 2021 to May 2, 2022. Our investigation concerns whether the board of directors of Spero have breached their fiduciary duties to the company. Spero, a clinical-stage bi.

SPERO ALERT: Bragar Eagel & Squire, P.C. is Investigating Spero Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Ms. Rajavelu brings over two decades of experience in the life sciences sector focused on strategic growth, financing, M&A, and investor relations. Ms. Rajavelu brings over two decades of experience in the life sciences sector focused on strategic growth, financing, M&A, and investor relations.

Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

Spero Therapeutics, Inc. (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Spero Therapeutics, Inc. (SPRO) Rating Upgrade to Buy

NEW YORK , Oct. 11, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Spero Therapeutics, Inc. (NASDAQ: SPRO). If you are a shareholder of Spero Therapeutics, Inc. and want to receive additional information and protect your investments free of charge, please visit us at: https://pjlfirm.com/spero-therapeutics-inc/ You may also contact Robert H.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Spero Therapeutics, Inc. (NASDAQ: SPRO) for Potential Breaches of Fiduciary Duty By Its Board of Directors

CAMBRIDGE, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at Cantor Fitzgerald's Global Healthcare 2023 Investor Conference, which will be held on September 26-28, 2023, at the Intercontinental Barclay Hotel in New York, NY. Details are as follows:

Spero Therapeutics to Present at Cantor's Global Healthcare 2023 Investor Conference

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the H.C. Wainwright 25th Annual Global Investment Conference, which is taking place September 11-13, 2023, at the Lotte New York Palace Hotel in New York, NY. Details are as follows:

Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

Spero Therapeutics, Inc. (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Spero Therapeutics, Inc. (SPRO) Upgraded to Strong Buy: What Does It Mean for the Stock?

The heavy selling pressure might have exhausted for Spero Therapeutics, Inc. (SPRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -11.72% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a Turnaround

CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Thursday, August 10, 2023 at 4:30 p.m. ET to report its second quarter 2023 financial results and provide an update on its business and pipeline.

Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

Spero Therapeutics shares soared after the clinical-stage biopharmaceutical company announced that it has received special protocol approval from the United States Food and Drug Administration (FDA) for the design and size of its Phase 3 study of its investigational therapeutic tebipenem HBr in patients with complicated urinary tract infection (cUTI), including acute pyelonephritis (AP). Shares of the Cambridge, Massachusetts-based company, which is focused on developing and commercializing treatments for rare diseases and multi-drug resistant bacterial infections, had added 14.1% at US$1.62 on Monday afternoon.

Spero Therapeutics shares rise on FDA approval of pivotal complicated UTI trial

Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q 2023

Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr

Spero is eligible to receive up to $525 million in development and sales milestone payments as well as royalties on net product sales under the agreement with GSK. In addition, Spero has two other assets that will soon be evaluated in proof-of-concept studies, both of which address significant unmet medical needs and have high commercial potential. The lead compound, SPR720, could be approved under an accelerated approval pathway and offers potential blockbuster status with peak sales of up to $1 billion.

Spero Therapeutics: The Multi-Asset Pipeline Could Outpace The Tebipenem HBr Deal With GSK

Sath Shukla, current Spero Chief Financial Officer, will bring more than 20 years of strategic and financial leadership to the role of CEO, to be effective August 1, 2023

Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer

Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Ted Jenkins – Vice President, Investor Relations and Strategic Finance Ankit Mahadevia – Chief Executive Officer Sath Shukla – Chief financial Officer Kamal Hamed – Chief Medical Officer Conference Call Participants Louise Chen – Cantor Ritu Baral – TD Cowen Gavin Clark-Gartner – Evercore ISI Boobalan Pachaiyappan – H.C. Wainwright Operator Good afternoon, and welcome to the Spero Therapeutics First Quarter 2023 Financial Results Conference Call.

Spero Therapeutics, Inc. (SPRO) Q1 2023 Earnings Call Transcript

Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $1.01 per share a year ago.

Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Tops Revenue Estimates

Phase 2 trial of SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD) on track for top line data readout in 1H 2024

Spero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business Update

CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Thursday, May 11, 2023 at 4:30 p.m. ET to report its first quarter 2023 financial results and provide an update on its business and pipeline.

Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Spero's management team will present and be available for one-on-one meetings at the H.C. Wainwright BioConnect Investor Conference at NASDAQ in New York City, on May 2, 2023. Details are as follows:

Spero Therapeutics to Present at Upcoming Investor Conference

Spero Therapeutics: Massive Partnership Deal Still Not Properly Valued By The Market.

Spero Therapeutics: Massive Partnership Deal Still Not Properly Valued By The Market

CAMBRIDGE, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced two poster presentations at the 33r d European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held April 15-18, 2023, in Copenhagen, Denmark.

Spero Therapeutics to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases

Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Ted Jenkins - VP & Head, IR Ankit Mahadevia - Co-Founder, President, CEO & Director Kamal Hamed - Chief Medical Officer Satyavrat Shukla - CFO & Treasurer Conference Call Participants Louise Chen - Cantor Fitzgerald & Co. Operator Good afternoon, and welcome to Spero Therapeutics Fourth Quarter and Year-End 2022 Financial Results Conference Call. [Operator Instructions].

Spero Therapeutics, Inc. (SPRO) Q4 2022 Earnings Call Transcript

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 237.50% and 2,865.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Beat Estimates

Initiated proof-of-concept Phase 2 trial of SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD); top line data expected in 1H 2024

News for Spero Therapeutics Stock (SPRO)